Charles Schwab
GSK icon

Charles Schwab’s GSK GSK Stock Holding History

Charles Schwab’s Portfolio GSK Stock Details GSK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$20.4M Buy
388,713
+52,207
+16% +$2.76M ﹤0.01% 1824
2026
Q1 		$18.6M Buy
336,506
+46,618
+16% +$2.53M ﹤0.01% 1786
2025
Q4 		$14.2M Buy
289,888
+35,754
+14% +$1.67M ﹤0.01% 1957
2025
Q3 		$11M Buy
254,134
+47,469
+23% +$1.85M ﹤0.01% 2074
2025
Q2 		$7.94M Buy
206,665
+35,520
+21% +$1.36M ﹤0.01% 2128
2025
Q1 		$6.63M Buy
171,145
+44,498
+35% +$1.63M ﹤0.01% 2150
2024
Q4 		$4.28M Buy
126,647
+5,044
+4% +$182K ﹤0.01% 2403
2024
Q3 		$4.97M Buy
121,603
+14,687
+14% +$601K ﹤0.01% 2381
2024
Q2 		$4.12M Buy
106,916
+15,224
+17% +$640K ﹤0.01% 2427
2024
Q1 		$3.93M Buy
91,692
+28,181
+44% +$1.16M ﹤0.01% 2374
2023
Q4 		$2.35M Buy
63,511
+18,807
+42% +$675K ﹤0.01% 2563
2023
Q3 		$1.62M Buy
44,704
+19,816
+80% +$703K ﹤0.01% 2660
2023
Q2 		$887K Buy
24,888
+11,366
+84% +$408K ﹤0.01% 2812
2023
Q1 		$481K Buy
13,522
+5,368
+66% +$188K ﹤0.01% 2964
2022
Q4 		$287K Buy
+8,154
New +$272K ﹤0.01% 3123
2021
Q1 		– Sell
-900,000
Closed -$41.4M – 3502
2020
Q4 		$41.4M Buy
900,000
+266,000
+42% +$12.2M 0.02% 893
2020
Q3 		$29.8M Buy
634,000
+10,000
+2% +$501K 0.01% 948
2020
Q2 		$31.8M Sell
624,000
-48,000
-7% -$2.46M 0.02% 855
2020
Q1 		$31.8M Buy
672,000
+29,680
+5% +$1.58M 0.02% 713
2019
Q4 		$37.7M Sell
642,320
-29,680
-4% -$1.65M 0.02% 799
2019
Q3 		$35.9M Buy
672,000
+16,000
+2% +$823K 0.02% 779
2019
Q2 		$32.8M Hold
656,000
– – 0.02% 810
2019
Q1 		$34.3M Buy
+656,000
New +$32.8M 0.02% 764

Other funds holding GSK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
JEST
JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Charles Schwab's GSK Position: Q2 2026 in Review

Charles Schwab increased its GSK (GSK) stake by 16% in Q2 2026, buying an estimated $2.76M and bringing the position to 388,713 shares worth $20.4M. The position accounts for ﹤0.01% of the portfolio, ranked #1824.

Charles Schwab first reported a position in GSK in Q1 2019 and has held it in 23 quarters since. The position peaked at $41.4M in Q4 2020. 1,040 funds tracked by Wall St. Rank hold GSK as of Q2 2026.

  • Charles Schwab held 388,713 shares of GSK worth $20.4M as of Q2 2026.
  • Charles Schwab bought 52,207 GSK shares in Q2 2026, an estimated $2.76M.
  • GSK made up ﹤0.01% of Charles Schwab's portfolio in Q2 2026, its #1824 holding.
  • Charles Schwab first reported a position in GSK in Q1 2019 and has held it in 23 quarters since.
  • Charles Schwab's GSK position peaked at $41.4M in Q4 2020.
  • 1,040 funds tracked by Wall St. Rank held GSK as of Q2 2026.

Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.